Basics Altimmune, Inc. Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. IPO Date: May 22, 2017 Sector: Healthcare Industry: Biotech Market Cap: $429.87M Activated in VL: True Average Daily Range Avg Daily Range: $0.31 | 4.16% Avg Daily Range (30 D): $0.17 | 3.01% Avg Daily Range (90 D): $0.17 | 3.08% Institutional Daily Volume Avg Daily Volume: 1.72M Avg Daily Volume (30 D): 2.2M Avg Daily Volume (90 D): 2.29M Trade Size Avg Trade Size (Sh.): 159 Avg Trade Size (Sh.) (30 D): 132 Avg Trade Size (Sh.) (90 D): 137 Institutional Trades Total Inst.Trades: 1,386 Avg Inst. Trade: $1.74M Avg Inst. Trade (30 D): $1M Avg Inst. Trade (90 D): $.94M Avg Inst. Trade Volume: .18M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2M Avg Closing Trade (30 D): $1.01M Avg Closing Trade (90 D): $.94M Avg Closing Volume: 220.07K     News Apr 30, 2025 @ 8:51 AM Will Pfizer Will Acquire Altimmune or Viking Thera... Source: The Motley Fool Mar 22, 2025 @ 10:44 AM Buying These Dirt-Cheap Stocks Could Be a Brillian... Source: The Motley Fool Feb 21, 2025 @ 6:00 PM Evolving Landscape of Obesity: Key Market Insights... Source: Delveinsight Jan 30, 2025 @ 4:03 PM Sprout Social, Altimmune, Equinix, and Globe Life ... Source: Johnson Fistel, Llp Dec 19, 2024 @ 11:35 PM Why Altimmune Was Such a Robustly Healthy Stock on... Source: Eric Volkman Financials   TTM Q3 2024 Q2 2024 Basic EPS $-.26 $-.32 $-.35 Diluted EPS $-.26 $-.32 $-.35 Revenue $ .01M $ .01M $ .01M Gross Profit $ $ $ Net Income / Loss $ -19.58M $ -22.85M $ -24.64M Operating Income / Loss $ -21.82M $ -24.77M $ -26.75M Cost of Revenue $ $ $ Net Cash Flow $ 12.18M $ -25.65M $ -21.85M PE Ratio     Splits Sep 14, 2018:   1:30 May 05, 2017:   1:10 May 04, 2017:   1:10 Jul 25, 2007:   1:50